

Christian Beisland

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3935733/publications.pdf>

Version: 2024-02-01

94
papers

2,142
citations

304368

22
h-index

253896

43
g-index

99
all docs

99
docs citations

99
times ranked

2860
citing authors

#	ARTICLE	IF	CITATIONS
1	IPSS "both question" score predicts health-related quality of life better than total IPSS score. <i>World Journal of Urology</i> , 2022, 40, 765-772.	1.2	3
2	Management of Bladder Pain Syndrome (BPS): A Practical Guide. <i>Advances in Urology</i> , 2022, 2022, 1-9.	0.6	4
3	Thulium Fibre Laser versus Holmium:YAG for Ureteroscopic Lithotripsy: Outcomes from a Prospective Randomised Clinical Trial. <i>European Urology</i> , 2022, 82, 73-79.	0.9	78
4	Rules and regulations for a pregnant endourologist: the European perspective. <i>World Journal of Urology</i> , 2022, 40, 857-864.	1.2	6
5	Reply to Hyung Joon Kim and Khurshid R. Ghani's Letter to the Editor re: Åyvind Ulvik, Mathias SÅrstrand ÅtsÅy, Patrick JuliebÅ-Jones, Peder GjengstÅ, Christian Beisland. Thulium Fibre Laser Versus Holmium:YAG for Ureteroscopic Lithotripsy: Outcomes from a Prospective Randomised Clinical Trial. <i>Eur Urol</i> . In press. https://doi.org/10.1016/j.eururo.2022.02.027 . <i>European Urology</i> , 2022, . . .	0.9	0
6	Reply to Frederic Panthier, Alba Sierra, and Olivier Traxer's Letter to the Editor re: Åyvind Ulvik, Mathias SÅrstrand ÅtsÅy, Patrick JuliebÅ-Jones, Peder GjengstÅ, Christian Beisland. Thulium Fibre Laser Versus Holmium:YAG for Ureteroscopic Lithotripsy: Outcomes from a Prospective Randomised Clinical Trial. <i>Eur Urol</i> . In press. https://doi.org/10.1016/j.eururo.2022.02.027 . <i>European Urology</i> , 2022, . . .	0.9	0
7	Reply to Alan J. Yaghoubian, Jonathan A. Khusid, and Mantu Gupta's Letter to the Editor re: Åyvind Ulvik, Mathias SÅrstrand ÅtsÅy, Patrick JuliebÅ-Jones, Peder GjengstÅ, Christian Beisland. Thulium Fibre Laser Versus Holmium:YAG for Ureteroscopic Lithotripsy: Outcomes from a Prospective Randomised Clinical Trial. <i>Eur Urol</i> . In press. https://doi.org/10.1016/j.eururo.2022.02.027 . <i>European Urology</i> , 2022, . . .	0.9	0
8	Serum levels of the IL-6 family of cytokines predict prognosis in renal cell carcinoma (RCC). <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 19-30.	2.0	23
9	The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery"Results from RECUR Consortium. <i>European Urology Oncology</i> , 2021, 4, 473-482.	2.6	33
10	Higher than expected and significantly increasing incidence of upper tract urothelial carcinoma. A population based study. <i>World Journal of Urology</i> , 2021, 39, 3385-3391.	1.2	25
11	Preoperative predictors of pathological tumour stage and prognosis may be used when selecting candidates for intensified treatment in upper tract urothelial carcinoma. <i>Scandinavian Journal of Urology</i> , 2021, 55, 100-107.	0.6	2
12	The epithelial"mesenchymal transition regulators Twist, Slug, and Snail are associated with aggressive tumour features and poor outcome in prostate cancer patients. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 253-270.	1.3	20
13	Pattern, timing and predictors of recurrence after surgical resection of chromophobe renal cell carcinoma. <i>World Journal of Urology</i> , 2021, 39, 3823-3831.	1.2	2
14	Should patients with low-risk renal cell carcinoma be followed differently after nephron-sparing surgery vs radical nephrectomy?. <i>BJU International</i> , 2021, 128, 386-394.	1.3	5
15	Prevalence, Disease-free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e92-e99.	0.9	30
16	Current Status of Intravesical Therapies for Bladder Pain Syndrome (BPS): A Narrative Review of Emerging Evidence. <i>Urology</i> , 2021, 156, e48-e57.	0.5	5
17	The levels of IL-6 and soluble IL-33R are increased in the renal vein during surgery for clear cell renal cell carcinoma. <i>Cytokine</i> , 2021, 144, 155586.	1.4	2
18	Current status of thulium fibre laser lithotripsy: an up-to-date review. <i>BJU International</i> , 2021, 128, 531-538.	1.3	31

#	ARTICLE	IF	CITATIONS
19	Endourological management of encrusted ureteral stents: An up-to-date guide and treatment algorithm on behalf of the European Association of Urology Young Academic Urology Urolithiasis Group. <i>Central European Journal of Urology</i> , 2021, 74, 571-578.	0.2	4
20	AGAP2-AS1 as a prognostic biomarker in low-risk clear cell renal cell carcinoma patients with progressing disease. <i>Cancer Cell International</i> , 2021, 21, 690.	1.8	7
21	Tumour architecture, grade and location remain predictors of non-organ-confined upper tract urothelial carcinoma at time of radical nephroureterectomy: results from a multicenter Norwegian external validation study. <i>World Journal of Urology</i> , 2020, 38, 717-723.	1.2	1
22	The Biological Context of C-Reactive Protein as a Prognostic Marker in Renal Cell Carcinoma: Studies on the Acute Phase Cytokine Profile. <i>Cancers</i> , 2020, 12, 1961.	1.7	9
23	Cytoreductive nephrectomy in primary metastatic clear cell renal cell carcinoma. <i>Scandinavian Journal of Urology</i> , 2020, 54, 500-500.	0.6	0
24	In memory of Alexander Schultz 1947–2020. <i>Scandinavian Journal of Urology</i> , 2020, 54, 363-363.	0.6	1
25	Personality and educational level determine self-reported health-related quality-of-life and distress in patients with renal tumors awaiting radical surgery. <i>Scandinavian Journal of Urology</i> , 2020, 54, 304-312.	0.6	4
26	Non-metastatic prostate cancer: rationale for conservative treatment and impact on disease-related morbidity and mortality in the elderly. <i>Scandinavian Journal of Urology</i> , 2020, 54, 105-109.	0.6	5
27	Magnetic resonance radiomics for prediction of extraprostatic extension in non-favorable intermediate- and high-risk prostate cancer patients. <i>Acta Radiologica</i> , 2020, 61, 1570-1579.	0.5	29
28	Assessing Extraprostatic Extension with Multiparametric MRI of the Prostate: Mehrlivand Extraprostatic Extension Grade or Extraprostatic Extension Likert Scale?. <i>Radiology Imaging Cancer</i> , 2020, 2, e190071.	0.7	17
29	A prospective phase I trial of dendritic cell-based cryoimmunotherapy in metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3029-3029.	0.8	6
30	AGAP2-AS1 as a potential marker for development of distant metastases in surgically treated low-risk clear cell renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 732-732.	0.8	1
31	FOXC2 expression and epithelial–mesenchymal phenotypes are associated with castration resistance, metastasis and survival in prostate cancer. <i>Journal of Pathology: Clinical Research</i> , 2019, 5, 272-286.	1.3	25
32	Transcriptome-proteome integration of archival human renal cell carcinoma biopsies enables identification of molecular mechanisms. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 316, F1053-F1067.	1.3	15
33	Elevated plasma interleukin 6 predicts poor response in patients treated with sunitinib for metastatic clear cell renal cell carcinoma. <i>Cancer Treatment and Research Communications</i> , 2019, 19, 100127.	0.7	14
34	Increased use of cross-sectional imaging for follow-up does not improve post-recurrence survival of surgically treated initially localized R.C.C.: results from a European multicenter database (R.E.C.U.R.). <i>Scandinavian Journal of Urology</i> , 2019, 53, 14-20.	0.6	15
35	Intensive Imaging-based Follow-up of Surgically Treated Localised Renal Cell Carcinoma Does Not Improve Post-recurrence Survival: Results from a European Multicentre Database (RECUR). <i>European Urology</i> , 2019, 75, 261-264.	0.9	30
36	Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma: RECUR Database Analysis. <i>European Urology Focus</i> , 2019, 5, 857-866.	1.6	67

#	ARTICLE	IF	CITATIONS
37	Prevalence, disease-free (DFS) and overall (OS) survival of contemporary high-risk renal cell carcinoma (RCC) patients eligible for adjuvant checkpoint inhibitor trials: A RECUR database analysis.. Journal of Clinical Oncology, 2019, 37, 636-636.	0.8	2
38	Tumour cell expression of interleukin 6 receptor $\hat{\pm}$ is associated with response rates in patients treated with sunitinib for metastatic clear cell renal cell carcinoma. Journal of Pathology: Clinical Research, 2018, 4, 114-123.	1.3	15
39	Real-life use of diagnostic biopsies before treatment of kidney cancer: results from a Norwegian population-based study. Scandinavian Journal of Urology, 2018, 52, 38-44.	0.6	5
40	Optimising preoperative risk stratification tools for prostate cancer using mpMRI. European Radiology, 2018, 28, 1016-1026.	2.3	18
41	Intensity-based volumetric registration of magnetic resonance images and whole-mount sections of the prostate. Computerized Medical Imaging and Graphics, 2018, 63, 24-30.	3.5	17
42	Dictionary-based through-plane interpolation of prostate cancer T2-weighted MR images. , 2018, , .		0
43	CRF-Based Clustering of Pharmacokinetic Curves from Dynamic Contrast-Enhanced MR Images. , 2018, , .		0
44	Use of venous-thrombotic-embolic prophylaxis in patients undergoing surgery for renal tumors: a questionnaire survey in the Nordic countries (The NORENCA -2 study). Research and Reports in Urology, 2018, Volume 10, 181-187.	0.6	2
45	Novel protein signatures suggest progression to muscular invasiveness in bladder cancer. PLoS ONE, 2018, 13, e0206475.	1.1	4
46	Fine needle aspirates of kidneys: a promising tool for RNA sequencing in native and transplanted kidneys. BMC Nephrology, 2018, 19, 221.	0.8	7
47	FP100FINE NEEDLE ASPIRATES OF KIDNEYS ARE USABLE FOR RNASEQUENCING LIKE REGULAR CORE BIOPSIES. Nephrology Dialysis Transplantation, 2018, 33, i80-i80.	0.4	0
48	National Norwegian Practice Patterns for Surgical Treatment of Kidney Cancer Tumors $\hat{\approx}$ 7 cm: Adherence to Changes in Guidelines May Improve Overall Survival. European Urology Oncology, 2018, 1, 252-261.	2.6	4
49	External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. World Journal of Urology, 2018, 36, 1973-1980.	1.2	10
50	Expanding the Utilization of Formalin-Fixed, Paraffin-Embedded Archives: Feasibility of miR-Seq for Disease Exploration and Biomarker Development from Biopsies with Clear Cell Renal Cell Carcinoma. International Journal of Molecular Sciences, 2018, 19, 803.	1.8	3
51	Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. New England Journal of Medicine, 2018, 379, 417-427.	13.9	684
52	CARMENA: Cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinomaâ€”Results of a phase III noninferiority trial.. Journal of Clinical Oncology, 2018, 36, LBA3-LBA3.	0.8	10
53	Imaging modalities used for follow-up of localized renal cell carcinoma (RCC) and subsequent effect on overall survival after recurrence: RECUR-database analysis.. Journal of Clinical Oncology, 2018, 36, 637-637.	0.8	2
54	Dendritic cell (DC) based cryoimmunotherapy (CryoIT) in a prospective phase I trial of metastatic castration resistant prostate cancer (mCRPC): Interim analysis.. Journal of Clinical Oncology, 2018, 36, e17014-e17014.	0.8	0

#	ARTICLE	IF	CITATIONS
55	Abstract CT066: Dendritic cell based cryoimmunotherapy associates with clinical variables and changes in T-cell receptor expression in a prospective phase I trial of metastatic castration resistant prostate cancer. , 2018, , .		0
56	Postoperative 30-day Mortality Rates for Kidney Cancer Are Dependent on Hospital Surgical Volume: Results from a Norwegian Population-based Study. <i>European Urology Focus</i> , 2017, 3, 300-307.	1.6	14
57	Use of diagnostic biopsies in kidney tumors. <i>Scandinavian Journal of Urology</i> , 2017, 51, 185-192.	0.6	0
58	Contemporary treatment of renal tumors: a questionnaire survey in the Nordic countries (the) Tj ETQq0 0 0 rgBT /Overlock 1Q Tf 50 622	0.6	9
59	Clear Cell Renal Cell Carcinoma is linked to Epithelial-to-Mesenchymal Transition and to Fibrosis. <i>Physiological Reports</i> , 2017, 5, e13305.	0.7	36
60	Incidental detection of renal cell carcinoma. <i>Scandinavian Journal of Urology</i> , 2017, 51, 178-184.	0.6	4
61	Rule-based data-driven approach for computer aided diagnosis of the peripheral zone prostate cancer from multiparametric MRI: Proof of concept. , 2017, , .		1
62	Reconstruction of high-resolution T2W MR images of the prostate using maximum a posteriori approach and Markov random field regularization. , 2017, , .		2
63	Predictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinoma. <i>BMC Urology</i> , 2017, 17, 74.	0.6	10
64	Overall survival in renal cell carcinoma after introduction of targeted therapies: a Norwegian population-based study. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 371-385.	1.0	26
65	Transcriptome Sequencing (RNAseq) Enables Utilization of Formalin-Fixed, Paraffin-Embedded Biopsies with Clear Cell Renal Cell Carcinoma for Exploration of Disease Biology and Biomarker Development. <i>PLoS ONE</i> , 2016, 11, e0149743.	1.1	50
66	Trends in stage-specific incidence of prostate cancer in Norway, 1980-2010: a population-based study. <i>BJU International</i> , 2016, 118, 547-555.	1.3	12
67	A positive Real-Time Elastography (RTE) combined with a Prostate Cancer Gene 3 (PCA3) score above 35 convey a high probability of intermediate- or high-risk prostate cancer in patient admitted for primary prostate biopsy. <i>BMC Urology</i> , 2016, 16, 39.	0.6	12
68	Author Reply. <i>Urology</i> , 2016, 93, 122-123.	0.5	0
69	RNA extraction for RNA sequencing of archival renal tissues. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2016, 76, 426-434.	0.6	38
70	Nephron Sparing Surgery Associated With Better Survival Than Radical Nephrectomy in Patients Treated for Unforeseen Benign Renal Tumors. <i>Urology</i> , 2016, 93, 117-123.	0.5	17
71	Development of a disease-specific health-related quality of life (HRQoL) questionnaire intended to be used in conjunction with the general European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) in renal cell carcinoma patients. <i>Acta Oncologica</i> , 2016, 55, 349-356.	0.8	11
72	Development and confirmation of potential gene classifiers of human clear cell renal cell carcinoma using next-generation RNA sequencing. <i>Scandinavian Journal of Urology</i> , 2016, 50, 452-462.	0.6	18

#	ARTICLE	IF	CITATIONS
73	Grading of urothelial carcinoma of the upper urinary tract according to the World Health Organization/International Society of Urological Pathology classification from 2004 is a valuable tool when considering whether a patient is suitable for endoscopic treatment. <i>Scandinavian Journal of Urology</i> , 2016, 50, 298-304.	0.6	4
74	A prospective risk-stratified follow-up programme for radically treated renal cell carcinoma patients: evaluation after eight years of clinical use. <i>World Journal of Urology</i> , 2016, 34, 1087-1099.	1.2	40
75	1.5-T multiparametric MRI using PI-RADS: a region by region analysis to localize the index-tumor of prostate cancer in patients undergoing prostatectomy. <i>Acta Radiologica</i> , 2015, 56, 500-511.	0.5	33
76	Prostate cancer antigen-3 (PCA3) and PCA3-based nomograms in the diagnosis of prostate cancer: an external validation of Hansen's nomogram on a Norwegian cohort. <i>Scandinavian Journal of Urology</i> , 2015, 49, 8-15.	0.6	8
77	Contemporary external validation of the Leibovich model for prediction of progression after radical surgery for clear cell renal cell carcinoma. <i>Scandinavian Journal of Urology</i> , 2015, 49, 205-210.	0.6	21
78	Health-related quality of life, personality and choice of coping are related in renal cell carcinoma patients. <i>Scandinavian Journal of Urology</i> , 2015, 49, 282-289.	0.6	11
79	Preoperative high levels of serum vascular endothelial growth factor are a prognostic marker for poor outcome after surgical treatment of renal cell carcinoma. <i>Scandinavian Journal of Urology</i> , 2015, 49, 388-394.	0.6	11
80	Overall survival (OS) in renal cell carcinoma (RCC) before and after the introduction of targeted therapies (TTs): A Norwegian population-based study (2000-2011). <i>Journal of Clinical Oncology</i> , 2015, 33, 443-443.	0.8	0
81	Health-related quality of life in long-term survivors after renal cancer treatment. <i>Scandinavian Journal of Urology</i> , 2014, 48, 52-64.	0.6	11
82	A positive real-time elastography is an independent marker for detection of high-risk prostate cancers in the primary biopsy setting. <i>BJU International</i> , 2014, 113, E90-E97.	1.3	16
83	Does a surgeon's annual radical prostatectomy volume predict the risk of positive surgical margins and urinary incontinence at one-year follow-up? - Findings from a prospective national study. <i>Scandinavian Journal of Urology</i> , 2013, 47, 92-100.	0.6	25
84	Combination of real-time elastography and urine prostate cancer gene 3 (PCA3) detects more than 97% of significant prostate cancers. <i>Scandinavian Journal of Urology</i> , 2013, 47, 211-216.	0.6	10
85	Incidentally detected renal cell carcinomas are highly associated with comorbidity and mortality unrelated to renal cell carcinoma. <i>Scandinavian Journal of Urology</i> , 2013, 47, 462-471.	0.6	21
86	Letter to the Editor. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 423.	0.6	1
87	Obesity is associated with an improved cancer-specific survival, but an increased rate of postoperative complications after surgery for renal cell carcinoma. <i>Scandinavian Journal of Urology and Nephrology</i> , 2012, 46, 348-357.	1.4	33
88	Observation Should be Considered as an Alternative in Management of Renal Masses in Older and Comorbid Patients. <i>European Urology</i> , 2009, 55, 1419-1429.	0.9	82
89	Multiple primary malignancies in patients with renal cell carcinoma: a national population-based cohort study. <i>BJU International</i> , 2006, 97, 698-702.	1.3	120
90	Presumed radically treated renal cell carcinoma: Recurrence of the disease and prognostic factors for subsequent survival. <i>Scandinavian Journal of Urology and Nephrology</i> , 2004, 38, 299-305.	1.4	21

#	ARTICLE	IF	CITATIONS
91	Vitiligo – an autoimmune side effect of intravesical bacillus Calmette – GuÃ©rin instillation?. Scandinavian Journal of Urology and Nephrology, 2004, 38, 182-183.	1.4	6
92	Natural and Clinical Course of Renal Cell Carcinoma – Better Prospect for the Patients. Scandinavian Journal of Surgery, 2004, 93, 97-101.	1.3	1
93	Renal Cell Carcinoma: Gender Difference in Incidental Detection and Cancer-specific Survival. Scandinavian Journal of Urology and Nephrology, 2002, 36, 414-418.	1.4	61
94	Nephrectomy – Indications, Complications and Postoperative Mortality in 646 Consecutive Patients. European Urology, 2000, 37, 58-64.	0.9	41